Related Experiment Video
Updated: Jun 17, 2026
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Efficacy of ligand-based targeting for the EGF system in cancer
Fusanori Yotsumoto1, Ayako Sanui, Tatsuya Fukami
1Department of Biochemistry, Fukuoka University, Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.
Abstract:
Although drugs inhibiting ErbB receptors such as epidermal growth factor receptor (EGFR) and HER2 have been developed as anticancer agents targeting the EGF family, they are not effective for all types of cancer and instead target only certain types. We propose the following four main reasons for these observations: (i) although seven EGFR ligands exist, effective inhibition of specific EGFR ligands may occur because their expression levels differ in different malignancies; (ii) suppressing EGFR ligands inhibits aggregation of EGFR and other ErbB receptors and activation of ERK and Akt signals; (iii) EGFR ligands may have various combinations for signal transduction through the EGFR pathway and other receptor signals; and (iv) the intracellular C-terminals of EGFR ligands move into the nucleus and strongly regulate cell proliferation. In this review, we describe important implications for targeted cancer therapy against EGFR ligands and describe the current situation in the development of ligand-based therapies for cancer.
Insights
Targeting epidermal growth factor receptor (EGFR) ligands offers a promising avenue for cancer therapy. Understanding EGFR ligand expression and signaling pathways is crucial for developing effective, targeted cancer treatments.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Epidermal growth factor receptor (EGFR) and HER2 inhibitors are used in cancer therapy.
- These drugs are not universally effective across all cancer types.
Purpose of the Study:
- To explore the reasons behind the variable efficacy of EGFR-targeted therapies.
- To review the implications of EGFR ligand-based cancer therapy.
Main Methods:
- Review of existing literature on EGFR ligands and their role in cancer.
- Analysis of signaling pathways involving EGFR and other ErbB receptors.
- Investigation of EGFR ligand interactions with cellular processes.
Main Results:
- Seven distinct EGFR ligands exist, with varying expression levels in different cancers.
- Inhibition of EGFR ligands impacts EGFR aggregation and downstream signaling (ERK, Akt).
- EGFR ligands utilize complex signaling combinations and can translocate to the nucleus to regulate proliferation.
Conclusions:
- The heterogeneity of EGFR ligands and their signaling mechanisms contributes to the differential response to EGFR-targeted drugs.
- Ligand-based therapeutic strategies for cancer hold significant potential.
- Further research into EGFR ligand biology is essential for advancing targeted cancer therapy.
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
02:40Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
01:22Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal